November 12, 2026
Health news, explained with evidence
LIVE
Study Finds Mixed Clinical Alignment in Reddit Mental Health Advice Papua New Guinean Tree Compound Shows Potential in Motor Neuron Disease Study Virtual Reality Lowers Pain and Anxiety in Pediatric Emergency Care, Study Finds New Parents with Intellectual Disabilities Face Significantly Higher Rates of Psychiatric Hospitalizations Study Highlights Emotional, Social, and Spiritual Needs in Pediatric Palliative Care Type 2 Diabetes Linked to a 53% Higher Risk of Alzheimer's Disease, Study Finds Brain Imaging Reveals Shared Memory Network in Mild Cognitive Impairment Early Sleep-Focused Telehealth Therapy May Help Trauma Survivors Access Mental Health Care FDA Issues Safety Warning Linking GLP-1 Medications to Rare Eye Condition Exploring Longevity Fitness Competitions: What Testing Healthspan Markers Means for Workout Routines Study Finds Mixed Clinical Alignment in Reddit Mental Health Advice Papua New Guinean Tree Compound Shows Potential in Motor Neuron Disease Study Virtual Reality Lowers Pain and Anxiety in Pediatric Emergency Care, Study Finds New Parents with Intellectual Disabilities Face Significantly Higher Rates of Psychiatric Hospitalizations Study Highlights Emotional, Social, and Spiritual Needs in Pediatric Palliative Care Type 2 Diabetes Linked to a 53% Higher Risk of Alzheimer's Disease, Study Finds Brain Imaging Reveals Shared Memory Network in Mild Cognitive Impairment Early Sleep-Focused Telehealth Therapy May Help Trauma Survivors Access Mental Health Care FDA Issues Safety Warning Linking GLP-1 Medications to Rare Eye Condition Exploring Longevity Fitness Competitions: What Testing Healthspan Markers Means for Workout Routines

FDA Review Highlights Three Decades of Adeno-Associated Virus Gene Therapy Submissions

❤️ Conditions & Care 1 min read 👁 0

A new analysis from US Food and Drug Administration researchers examines thirty years of adeno-associated virus gene therapy Investigational New Drug submissions, offering insights into regulatory holds and product development trends.

FDA Review Highlights Three Decades of Adeno-Associated Virus Gene Therapy Submissions❤️Conditions & Care

Photo: Nature Health Sciences

Key points

  • Analyzed IND submissions to the FDA spanning 1995 to 2025
  • Authored by researchers from the Center for Biologics Evaluation and Research
  • Identified common reasons for regulatory holds in AAV development

An evaluation of Investigational New Drug applications submitted to the US Food and Drug Administration between 1995 and 2025 details significant expansion in the development of adeno-associated virus vectors over a thirty-year span. Conducted by researchers from the agency's Center for Biologics Evaluation and Research and published in Nature Biotechnology, the review outlines the trajectory of these advanced therapeutic candidates and identifies recurring factors that prompt regulatory holds during the application process.

The findings offer a retrospective look at how vector-based applications have evolved, highlighting common hurdles that developers encounter when navigating clinical trial authorizations. While the report outlines widespread developmental trends within the regulatory pipeline, it remains an observational summary of past submissions rather than a step-by-step guideline for future clinical trial approvals.

What to know: Reviewing historical regulatory data helps developers anticipate agency feedback, but each therapeutic candidate undergoes distinct evaluation based on its individual preclinical profile. Readers considering participation in clinical trials or seeking information on emerging treatments should consult qualified medical professionals.

Source Nature Health Sciences — nature.com/articles/s41587-026-03378-9 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.